Table 1. Multiagent chemotherapy... | American Society of Hematology

Table 1.

Multiagent chemotherapy regimens used in BPDCN

Hematologic malignancy from which chemotherapy regimen was adopted	Chemotherapy regimen
AML	“7+3”: cytarabine, daunorubicin HiDAC: high-dose cytarabine
ALL	HCVAD: hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone ICE: ifosfamide, carboplatin, etoposide CALGB 9111: induction cyclophosphamide, daunorubicin, vincristine, prednisolone, asparaginase, and filgrastim
Lymphoma	CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone
Myeloma	Daratumumab⁸⁷^,⁸⁸ Lenalidomide and bortezomib⁸⁹^,¹²⁰

Hematologic malignancy from which chemotherapy regimen was adopted	Chemotherapy regimen
AML	“7+3”: cytarabine, daunorubicin HiDAC: high-dose cytarabine
ALL	HCVAD: hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone ICE: ifosfamide, carboplatin, etoposide CALGB 9111: induction cyclophosphamide, daunorubicin, vincristine, prednisolone, asparaginase, and filgrastim
Lymphoma	CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone
Myeloma	Daratumumab⁸⁷^,⁸⁸ Lenalidomide and bortezomib⁸⁹^,¹²⁰